Efficacy of Aripitan combined with Dexamethasone and Dorasetron in the treatment of nausea and vomiting caused by EP regimen chemotherapy for small cell lung cancer
GAO Jian XU Ximing CHEN Jiayu
Cancer Center, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China
Abstract：Objective To evaluate the efficacy of Aripitant combined with Dexamethasone and Dolasetron in the treatment of nausea and vomiting caused by EP regimen chemotherapy for small cell lung cancer. Methods Clinical data of 40 small cell lung cancer patients with initial treatment and definite pathological diagnosis from December 2017 to December 2019 in Cancer Center of Renmin Hospital of Wuhan University were retrospectively analyzed. All patients were divided into control group and experimental group according to random number table method, 20 cases in each group. All patients were given Etoposide and Cisplatin combined chemotherapy, control group was given preventive antiemetic therapy of intravenous drip of Dorasetron and oral Dexamethasone 30 minutes before chemotherapy, experimental group was given preventive antiemetic therapy of intravenous infusion of Dorasetron, oral Dexamethasone and Aripiptan 30 minutes before chemotherapy. Control of nausea and vomiting induced by chemotherapy in acute, delayed and whole stage and adverse reactions were compared between two groups. Results There were no significant differences in total effective rate of nausea control in acute phase, delayed phase and overall phase between two groups (P > 0.05). There was no significant difference in total effective rate of vomiting control in acute phase and overall phase between two groups (P > 0.05). Total effective rate of vomiting control in experimental group was higher than that in control group, and the difference was statistically significant (P < 0.05). The common adverse reactions of two groups were grade Ⅰ-Ⅱ, and there were no grade Ⅲ-Ⅳ adverse reactions. Conclusion Aripitan combined with Dexamethasone and Dorasetron has a good effect in the treatment of nausea and vomiting caused by EP regimen for small cell lung cancer, and the adverse reactions are small, especially it is effective for delayed vomiting.
高健 徐细明 陈嘉羽. 阿瑞匹坦联合地塞米松及多拉司琼治疗肺小细胞癌EP方案化疗致恶心呕吐的效果[J]. 中国医药导报, 2021, 18(5): 88-92,108.
GAO Jian XU Ximing CHEN Jiayu. Efficacy of Aripitan combined with Dexamethasone and Dorasetron in the treatment of nausea and vomiting caused by EP regimen chemotherapy for small cell lung cancer. 中国医药导报, 2021, 18(5): 88-92,108.
[1] Ferlay J，Colombet M，Soerjomataram I，et al. Estimating the global cancer incidence and mortality in 2018：GLOBOCAN sources and methods [J]. Int J Cancer，2019，44（8）：1941-1953.
[2] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018：68（6）：394-424.
[3] Jahchan NS，Jing SL，Bola B，et al. Identification and targeting of long-term tumor-propagating cells in small cell lung cancer [J]. Cell Rep，2016，16（3）：644-656.
[4] Yang S，Zhang Z，Wang Q. Emerging therapies for small cell lung cancer [J]. J Hematol Oncol，2019，12（1）：47.
[5] Zhao H，Ren D，Liu H，et al. Comparison and discussion of the treatment guidelines for small cell lung cancer [J]. Thorac Cancer，2018，9（77）：699-774.
[6] Kiernan JM，Conradi Stark J，Vallerand AH. Chemotherapy-induced nausea and vomiting mitigation with music interventions [J]. Oncol Nurs Forum，2018，45（1）：88-95.
[7] Razvi Y，Chan S，McFarlane T，et al. ASCO，NCCN，MASCC/ESMO：a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients [J]. Port Care Cancer，2019，27（1）：87-95.
[8] Storz E，Gschwend JE，Retz M. Chemotherapy-induced nausea and vomiting：current recommendations for prophylaxis [J]. Urologe A，2018，57（5）：532-542.
[9] Matsuzaki K，Ito Y，Fukuda M，et al. Placebo-controlled phase Ⅲ study comparing dexamethasone on day 1 to day 1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy [J]. J Clin Oncol，2016， 34：10019.
[10] Rapoport BL. Rolapitant：an NK-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting [J]. Rev Recent Clin Trials，2017，12（3）：193-201.
[11] Schnadig ID，Agajanian R，Dakhil C，et al. APF530 versus ondansetron，each in a guideline-recommended three-drug regimen，for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens：a post hoc subgroup analysis of the phase Ⅲ randomized MAGIC trial [J]. Cancer Manag Res，2017， 9：179-187.
[12] 罗德红，文中全，曹梦璐，等.阿瑞吡坦联合方案预防化疗相关恶心呕吐的临床效果分析[J].内蒙古医学杂志，2020，52（5）：527-530.
[13] 关莎莎，张丽沙，钟殿胜，等.阿瑞匹坦预防化疗诱导恶心呕吐的疗效分析[J].中国肺癌杂志，2018，21（10）：800-804．
[14] 蔡智慧，李卉，田肖芳，等.阿瑞匹坦联合昂丹司琼治疗乳腺癌化疗引起的恶心呕吐31例疗效观察[J].安徽医药，2020，24（2）：378-380．
[15] 张姣，刘华云，王玉花.阿瑞匹坦预防骨与软组织肿瘤患者接受高致吐化疗所致恶心、呕吐的研究[J].肿瘤药学，2019，9（2）：270-274．
[16] Tageja N，Groninger H. Chemotherapy-induced nausea and vomiting：an overview and comparison of three consensus guidelines [J]. Stgrad Med J，2016，92（1083）：34-40.
[17] de Wit R，Herrstedt J，Rapoport B，et al. The oral NK（1） antagonist，aprepitant，given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy：a combined analysis of two randomised，placebo-controlled phase Ⅲ clinical trials [J]. Eur J Cancer，2004，40（3）：403-410.
[18] 陈丽昆，程颖，张红雨.阿瑞吡坦在中国肺癌患者中预防高剂量顺铂引起恶心和呕吐的疗效[J].中国新药与临床杂志，2015，34（10）：757-763.
[19] Koth SM，Kolesar J. New options and controversies in the management of chemotherapy-induced nausea and vomiting [J]. Am J Health Syst Pharm，2017，74（11）：812-819.
[20] Kottschade L，Novotny P，Lyss A，et al. Chemotherapy-induced nausea and vomiting：incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 （Alliance） [J]. Cancer，2016，24（6）：2661-2667.
[21] Barbour SY. Management of patients with chemotherapy-induced nausea and vomiting [J]. J Adv Pract Oncol，2017，8（3）：303-308.
[22] Rojas C，Raje M，Tsukamoto T，et al. Molecular mechanisms of 5-HT（2） and NK（1） receptor antagonists in prevention of emesis [J]. Eur J Pharmacol，2014，722：26-37.
[23] Bo?觢njak SM，Gralla RJ，Schwartzberg L. Prevention of chemotherapy-induced nausea：the role of neurokinin-1 （NK-1） receptor antagonists [J]. Support Care Cancer，2017，25（5）：1661-1671.
[24] Babic T，Browning KN. The role of vagal neurocircuits inthe regulation of nausea and vomiting [J]. Eur J Pharmacol，2014，722（1433）：38.
[25] Kovács G，Wachtel AE，Basharova EV，et al. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy：a randomised，phase 3，double-blind，double-dummy，non-inferiority study [J]. Lancet Oncol，2016，17（3）：332-344.
[26] Okada Y，Oba K，Furukawa N，et al. One-Day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting：a systematic review and individual patient data-based meta-analysis [J]. Oncologist，2019，24（12）：1593-1600.
[27] Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies [J]. Am J Manag Care，2017，23（14 Suppl）：S259-S265.
[28] Patel MP，Woodring S，Randazzo DM，et al. Randomized open-label phase Ⅱ trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide [J]. Support Care Cancer，2020，28（5）：2229-2238.
[29] Kim JE，Jang JS，Kim JW，et al. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types [J]. Support Care Cancer，2017， 25（3）：801-809.
[30] Ito Y，Karayama M，Inui N，et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy [J]. Lung Cancer，2014，84（3）：259-264.
[31] Kitazaki T，Fukuda Y，Fukahori S，et al. Usefulness of antiemetic therapy with aprepitant，palonosetron，and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy [J]. Support Care Cancer，2015，23：185-190.
[32] Chasen M，Urban L，Schnadig I，et al. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy [J]. Support Care Cancer，2017，25（1）：85-92.
[33] Naito Y，Kai Y，Ishikawa T，et al. Chemotherapy-induced nausea and vomiting in patients with breast cancer：a prospective cohort study [J]. Breast Cancer，2020，27（1）：122-128.
2021, Vol. 18 
京公网安备 11010502046598号